

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 7, 2002, 15:40:13 ; Search time 154.28 Seconds

(without alignments)
23.046 Million cell updates/sec

Title: US-08-569-749-9

Perfect score: 295
Sequence: 1 PEOIASGFEYVGRNDVVC.....CMESGDDPWYEHAKFPFRC 48

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues

Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

A.Geneseq_1101:*

1: /SIDS2/gcgdata/geneseq/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/AA2001.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	295	100.0	48	18	AAW13551 Human c-IAP1 repea
2	295	100.0	438	17	AAW04583 Human inhibitor of
3	295	100.0	618	18	AAW19276 Human inhibitor of
4	295	100.0	618	18	AAW13585 Human c-IAP1. Hom
5	295	100.0	618	20	AAW13585 Human c-IAP1. Hom
6	283	95.9	618	18	AAW19583 Human cellular inh
7	283	95.9	618	19	AAW69296 Human H1AP-2 prote
8	282	95.6	48	18	AAW13552 Human c-IAP2 repea
9	282	95.6	604	18	AAW19747 Human inhibitor of
10	282	95.6	604	18	AAW19582 Human apoptosis in
11	282	95.6	604	18	AAW13546 Human c-IAP2. Hom

12	282	95.6	604	19	AAW69295 Human H1AP-1 prote
13	282	95.6	604	20	AAW52703 Human cellular inh
14	282	95.6	604	20	AAW33997 Human cellular inh
15	282	95.6	612	18	AAW13555 Murine c-IAP. Mus
16	282	95.6	612	19	AAW69299 Murine H1AP-2 prot
17	282	95.6	1141	22	AAW50694 Human APT2-MUT chl
18	276	93.6	591	18	AAW19586 Mouse apoptosis in
19	268	90.8	600	19	AAW69298 Murine H1AP-1 prot
20	258	87.5	602	18	AAW19585 Mouse apoptosis in
21	195	66.1	210	22	AAW5287 Human protein sequ
22	195	66.1	280	22	AAW31478 Amino acid sequenc
23	195	66.1	298	21	AAW84907 A human proliferat
24	195	66.1	298	21	AAW69182 Human inhibitor of
25	178	60.3	1232	17	AAW88217 Neuronal apoptosis
26	178	60.3	1295	20	AAW10950 Gonadotropic hormo
27	178	60.3	1295	20	AAW09540 Human apoptosis in
28	178	60.3	1403	18	AAW20032 Neuronal apoptosis
29	178	60.3	1403	18	AAW20033 Gonadotropic hormo
30	178	60.3	1403	20	AAW14079 Human NAIP protein
31	178	60.3	1403	20	AAW09539 Human NAIP protein
32	178	60.3	1403	21	AAW88053 Mouse inhibitor of
33	174	59.0	496	18	AAW19745 Human apoptosis in
34	174	59.0	497	18	AAW19581 Human X-linked inh
35	174	59.0	497	19	AAW69284 Human X-linked inh
36	174	59.0	497	21	AAW9985 Human XAP protein
37	174	59.0	497	21	AAW59451 Human IAP (an inh
38	171	58.0	236	21	AAW81440 Human IAP-like pro
39	171	58.0	236	22	AAW00365 Chimpanzee IAP-1lk
40	171	58.0	236	22	AAW00367 Gorilla IAP-1lk p
41	170	57.6	236	22	AAW48195 Drosophila mutant
42	160	54.2	434	22	AAW48188 Drosophila wild-ty
43	160	54.2	438	22	AAW48189 Drosophila mutant
44	160	54.2	438	22	AAW48189 Drosophila mutant
45	160	54.2	438	22	AAW48190 Drosophila mutant

ALIGNMENTS

AAW13551	RESULT 1
ID	AAW13551 standard: Protein: 48 AA.
AC	AAW13551:
XX	XX
DT	22-JUL-1997 (first entry)
DE	Human c-IAP1 repeat 3.
KW	IAP: inhibitor; apoptosis; RING finger domain; restinosis;
KW	myocardial infarction; nephritis; HIV.
OS	Homo sapiens.
XX	XX
PN	MO9706182-A1.
XX	XX
PD	20-FEB-1997.
XX	XX
PF	06-AUG-1996, 96WO-US12860.
XX	XX
PR	08-DEC-1995, 95US-0569749.
PR	08-AUG-1995, 95US-0512946.
XX	XX
PA	(TUL-) TULARIK INC.
XX	XX
PT	Goeddel DV, Rothe M.
XX	XX
DR	WPI: 1997-154209/14.
XX	XX
PT	Nucleic acids encoding cellular inhibitor of apoptosis proteins
PT	useful for apoptosis regulation in cells to reduce or increase
PT	apoptosis and for pharmacological screening
XX	XX

CC disease.
 XX
 SO Sequence 618 AA;
 Query Match 100.0%; Score 295; DB 18; Length 618;
 Best Local Similarity 100.0%; Pred. No. 5.3e-28;
 Matches 48; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 PEOIASAGFYVGRNDVKFCDCGGLRCWESGDDPWVEHAKWPRCE 48
 DB 287 peglasagfyyvgrndvkcfcctcdgglrcwesgddpwvehakwprce 334
 RESULT 4
 AAW13545
 ID AAW13545 standard; Protein: 618 AA.
 AC AAW13545;
 AD 22-JUL-1997 (first entry)
 DE Human c-IAP1.
 KM IAP: inhibitor; apoptosis; RING finger domain; restinosis;
 KW myocardial infarction; nephritis; HIV.
 OS Homo sapiens.
 PA WO9706182-A1.
 PN 20-FEB-1997.
 PD 06-AUG-1996; 96WO-US12860.
 PE 08-DEC-1995; 95US-0569749.
 PR 08-AUG-1995; 95US-0512946.
 PS (TULSA-) TULARIK INC.
 PI Goeddel DV, Rothe M;
 DR WPI: 1997-154209/14.
 DR N-PSDB; AAT61590.
 XX
 PT Nucleic acids encoding cellular inhibitor of apoptosis proteins -
 PT useful for apoptosis regulation in cells to reduce or increase
 PT apoptosis and for pharmacological screening
 PS Disclosure: Page 18-20; 35pp; English.
 XX
 CC The human cellular inhibitor of apoptosis proteins (c-IAP1/2 -
 CC AAT61590/T61591) comprise a series of defined structural domain
 CC repeats and/or a RING finger domain; in particular, at least two of
 CC a first domain repeat (AAW13547 or AAW13548), a second domain repeat
 CC (AAW13549 or AAW13550), and a third domain repeat (AAW13551 or AAW13552)
 CC and/or a RING finger domain (AAW13553 or AAW13554), or a consensus
 CC sequences derived from these human genes.
 CC The nucleic acid is used for recombinant prodn. of human cellular
 CC inhibitor of apoptosis protein which modulates apoptosis
 CC regulation. The nucleic acids are useful in therapies where
 CC increased cell-specific apoptosis is desired, e.g. in restinosis,
 CC inflammatory disease states, myocardial infarction, glomerular
 CC nephritis, transplant rejection and infectious diseases, e.g. HIV.
 CC They can also be used in conditions requiring a reduction in
 CC apoptosis.
 XX
 SO Sequence 618 AA;
 Query Match 100.0%; Score 295; DB 18; Length 618;
 Best Local Similarity 100.0%; Pred. No. 5.3e-28;
 Matches 48; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEOIASAGFYVGRNDVKFCDCGGLRCWESGDDPWVEHAKWPRCE 48
 DB 287 peglasagfyyvgrndvkcfcctcdgglrcwesgddpwvehakwprce 334
 RESULT 5
 AAW33998
 ID AAW33998 standard; Protein: 618 AA.
 AC AAW33998;
 AD 26-NOV-1999 (first entry)
 DE Human cellular inhibitor of apoptosis-1 sequence.
 KM Cellular inhibitor of Apoptosis-1; antisense; diagnostic; therapeutic;
 KW c-IAP-1; prophylaxis; infection; inflammation; tumor formation.
 OS Homo sapiens.
 PA US9598772-A.
 PN 28-SEP-1999.
 PD 03-DEC-1998; 98US-0205204.
 PE 03-DEC-1998; 98US-0205204.
 PR 03-DEC-1998; 98US-0205204.
 PS (ISIS-) ISIS PHARM INC.
 PI Bennett CF, Cowser LM, Ackermann EJ;
 DR WPI: 1999-561047/47.
 DR N-PSDB; AAZ22143.
 XX
 PT Antisense compounds complementary to Cellular Inhibitor of Apoptosis-1
 PT useful for e.g. diagnostics, therapeutics, and as research reagents -
 XX
 PS Example 13; Columns 41-46; 32pp; English.
 CC The invention provides antisense compounds of 8-30 nucleotides that
 CC inhibit the expression of human cellular inhibitor of apoptosis-1
 CC (c-IAP-1). The antisense compounds may be used for diagnostics,
 CC therapeutics (for modulating the expression of c-IAP-1), prophylaxis
 CC (e.g. to prevent or delay infection, inflammation, or tumor formation),
 CC as research reagents (e.g. to distinguish between members of a biological
 CC pathway) and in kits. The present sequence represents the human cellular
 CC inhibitor of apoptosis-1.
 XX
 SO Sequence 618 AA;
 Query Match 100.0%; Score 295; DB 20; Length 618;
 Best Local Similarity 100.0%; Pred. No. 5.3e-28;
 Matches 48; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 PEOIASAGFYVGRNDVKFCDCGGLRCWESGDDPWVEHAKWPRCE 48
 DB 287 peglasagfyyvgrndvkcfcctcdgglrcwesgddpwvehakwprce 334
 RESULT 6
 AAW19583
 ID AAW19583 standard; Protein: 618 AA.
 AC AAW19583;
 AD 02-SEP-1997 (first entry)
 DE Human apoptosis inhibitor HIAP-2.
 KW Apoptosis inhibitor; HIAP-2; HIV; AIDS; neurodegeneration;

KW myelodysplastic syndrome; ischemia; myocardial infarction; stroke;
 KW reperfusion injury; toxin-induced liver disease; gene therapy;
 KW diagnosis.

OS Homo sapiens.

XX Key Location/Qualifiers
 XX Domain 46..113
 FT /label= BIR-1
 FT Domain 184..250
 FT /label= BIR-2
 FT 269..336
 FT /label= BIR-3
 FT 560..605
 FT /label= Ring_zinc_finger

XX MO9706255-A2.

XX 20-FEB-1997.

XX 05-AUG-1996; 96MO-IB01022.

XX 22-DEC-1995; 95US-0576956.

XX 04-AUG-1995; 95US-0511485.

XX (UYOT-) UNIV OTTAWA.

XX Baird S, Korneluk RG, Liston P, Mackenzie AE;

XX WPI: 1997-154262/14.

XX N-PSDB; AAT70838.

XX Nucleic acid encoding an inhibitor of apoptosis polypeptide - used
 PT to inhibit apoptosis in e.g. HIV or AIDS patients, and for detection
 PT of susceptibility to apoptotic disease

XX Claim 27; Page 75-77; 219pp; English.

XX Human XIAP, HIAP-1 and HIAP-2 and murine M-XIAP, M-HIAP-1 and
 CC M-HIAP-2 (AAW19581-86) are a new class of mammalian proteins that
 CC are inhibitors of apoptosis (IAP) and which are characterised by
 CC the presence of a ring zinc finger domain (see also AAW19587) and at
 CC least one BIR (baculovirus IAP repeat) domain (see also AAW19588).
 CC The HIAP amino acid sequences were deduced from cDNA clones (AAT70837
 CC and AAT70838) from a human liver library. IAP polypeptides can be
 CC expressed in host cells (in vitro or in vivo) and used in methods
 CC for treating diseases and disorders involving apoptosis, esp. in a
 CC human diagnosed as HIV-positive or as having AIDS, a
 CC neurodegenerative disease, a myelodysplastic syndrome or an
 CC ischaemic injury, selected from myocardial infarction, stroke,
 CC reperfusion injury, or a toxin-induced liver disease.

XX Sequence 618 AA;

Query Match 95.9%; Score 283; DB 18; Length 618;

Best Local Similarity 97.9%; Pred. No. 1.6e-26;

Matches 47; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 PEQLASAGFYVGRNDVAKFCPCDGLRCMESGDDPWVWEHAKWPRCE 48
 DB 287 peqlasagfyvgrndvkcfcgdcgdlrcwesgddpwvehakwprce 334

RESULT 7

AAW69296

XX AAW69296 standard; Protein; 618 AA.

XX 13-NOV-1998 (first entry)

DE Human HIAP-2 protein.

XX Inhibitor of apoptosis protein; apoptosis enhancer; NAIP polypeptide;
 KW proliferative disease; IAP; therapy; cancer; human; HIAP-2 protein.
 KW diagnosis.

OS Homo sapiens.

XX MO9835693-A2.

XX 20-AUG-1998.

XX 13-FEB-1998; 98MO-IB00781.

XX 13-FEB-1997; 97US-0800929.

XX (UYOT-) UNIV OTTAWA.

XX Baird S, Korneluk R, Liston P, Mackenzie AE, Pratt C;

XX Tsang B;

XX WPI: 1998-467164/40.

XX N-PSDB; AAV55040.

XX Disclosure: Fig 3; 147pp; English.

XX This sequence is the human HIAP-2 protein, which is a inhibitor of
 CC apoptosis protein (IAP), and can be used in the method of the invention.
 CC The method is for enhancing apoptosis in cells from a mammal with
 CC proliferative disease by treatment with a compound that inhibits
 CC biological activity of an IAP or NAIP polypeptide. The inhibitory
 CC compounds are used to treat proliferative diseases, specially cancers of
 CC ovary, breast, pancreas, lymph nodes, skin, blood, lung, brain, kidney,
 CC liver, nasopharynx, thyroid, central nervous system, prostate, colon,
 CC rectum, cervix or endometrium, particularly to increase their sensitivity
 CC to chemotherapeutic agents. High levels of the IAP or NAIP proteins are
 CC detected in many cancers and are associated with poor prognosis,
 CC resistance to chemotherapeutic agents and mutations in p53 (it is
 CC suggested that wild-type p53 suppresses transcription of the IAP or NAIP
 CC genes). Transgenic animals are used for testing the effects of antisense
 CC oligonucleotides and for screening for the inhibitors.

XX Sequence 618 AA;

Query Match 95.9%; Score 283; DB 19; Length 618;

Best Local Similarity 97.9%; Pred. No. 1.6e-26;

Matches 47; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 PEQLASAGFYVGRNDVAKFCPCDGLRCMESGDDPWVWEHAKWPRCE 48
 DB 287 peqlasagfyvgrndvkcfcgdcgdlrcwesgddpwvehakwprce 334

RESULT 8

AAW13552

XX AAW13552 standard; Protein; 48 AA.

XX 22-JUL-1997 (first entry)

XX Human c-IAP2 repeat 3.

XX IAP; inhibitor; apoptosis; RING finger domain; restinosis;

XX myocardial infarction; nephritis; HIV.

XX Homo sapiens.

XX MO9706182-A1.

XX PD 20-FEB-1997.
XX PF
XX PF 06-AUG-1996; 96WO-US12860.
XX PR 08-DEC-1995; 95US-0569749.
XX PR 08-AUG-1995; 95US-0512946.
XX PA (TULA-) TULARIX INC.
XX PI Goeddel DV, Rothe M;
XX WPI; 1997-154209/14.
XX Nucleic acids encoding cellular inhibitor of apoptosis proteins -
PT useful for apoptosis regulation in cells to reduce or increase
PT apoptosis and for pharmacological screening
XX Claim 3; page 25; 35pp; English.
XX PS
XX CC The human cellular inhibitor of apoptosis proteins (c-IAP1/2 -
CC AAT61590/761591) comprise a series of defined structural domain
CC repeats and/or a RING finger domain; in particular, at least two of
CC a first domain repeat (AAW13547 or AAW13548), a second domain repeat
CC (AAW13549 or AAW13550), and a third domain repeat (AAW13551 or AAW13552)
CC and/or a RING finger domain (AAW13553 or AAW13554), or a consensus
CC sequences derived from these human genes.
CC The nucleic acid is used for recombinant prodn. of human cellular
CC inhibitor of apoptosis protein which modulates apoptosis
CC regulation. The nucleic acids are useful in therapies where
CC increased cell-specific apoptosis is desired, e.g. in restitosis,
CC inflammatory disease states, myocardial infarction, glomerular
CC nephritis, transplant rejection and infectious diseases; e.g. HIV.
CC They can also be used in conditions requiring a reduction in
CC apoptosis.
XX Sequence 48 AA:
SQ
Query Match 95.6%; Score 282; DB 18; Length 48;
Best Local Similarity 93.8%; Pred. No. 1.4e-27;
Matches 45; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1 PEOIASAGFYVGRNDVRCFCDCGGLRCWESGDDPWVYHAKWPRCE 48
|||
DB 1 pqlaasgfyvgrndvrcfcdcgglrcwesgddpwvghakwprce 48
RESULT 9
AAW19747
ID AAW19747 standard; Protein: 604 AA.
XX AC AAW19747;
XX DT 16-SEP-1997 (first entry)
XX DE Human inhibitor of apoptosis protein homologue MHC.
XX DE Inhibitor of apoptosis protein; IAP; mammalian IAP homologue; MHC;
KW degenerative disease; infectious disease; autoimmune disease;
KW cancer; therapy; diagnosis.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT 29..37
FT /label= BIR
FT 169..236
FT /label= BIR
FT 255..323
FT /label= BIR
FT 556..593
FT /label= RING_finger

XX PN W09723501-AA.
XX PD 03-JUL-1997.
XX PF 20-DEC-1996; 96WO-AU00827.
XX PR 22-DEC-1995; 95AU-0007275.
XX PA (AMRA-) AMRAD OPERATIONS PTY LTD.
XX PI Vaux DL;
XX WPI; 1997-350966/32.
XX DR N-PSDB; AAT72712.
XX Isolated protein homologues of viral inhibitors of apoptosis - used
PT to modulate apoptosis for treatment of degenerative, infectious or
PT autoimmune diseases and cancer
XX Claim 9; Page 58-62; 136pp; English.
XX PS
XX CC Mammalian IAP homologue C (MHC) (AAW19747) is a human homologue of
CC baculovirus inhibitor of apoptosis protein (IAP). Its amino acid
CC sequence was deduced from a cDNA clone (see also AAT72712) isolated
CC from a human foetal liver cDNA library using primers based on
CC human EST sequences that resembled the BIR repeats of Oryza
CC pseudotsugata polyhedrosis virus IAP. IAP homologues (see also
CC AAW19745-46 and AAW19748-52) and their derivatives and chemical
CC analogues can be used in methods for modulating apoptosis in animal
CC cells, specifically for treatment, by inhibition, of degenerative
CC and infectious disease or, by promotion, of cancer and autoimmune
CC disease.
XX Sequence 604 AA:
SQ
Query Match 95.6%; Score 282; DB 18; Length 604;
Best Local Similarity 93.8%; Pred. No. 2e-26;
Matches 45; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1 PEOIASAGFYVGRNDVRCFCDCGGLRCWESGDDPWVYHAKWPRCE 48
|||
DB 273 pqlaasgfyvgrndvrcfcdcgglrcwesgddpwvghakwprce 320
RESULT 10
AAW19582
ID AAW19582 standard; Protein: 604 AA.
XX AC AAW19582;
XX DT 02-SEP-1997 (first entry)
XX DE Human apoptosis inhibitor HIAP-1.
XX DE Apoptosis inhibitor; HIAP-1; HIV; AIDS; neurodegeneration;
KW myelodysplastic syndrome; ischaemia; myocardial infarction; stroke;
KW reperfusion injury; toxin-induced liver disease; gene therapy;
KW diagnosis.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT 29..36
FT /label= BIR-1
FT 169..235
FT /label= BIR-2
FT 255..322
FT /label= BIR-3
FT 546..591
FT /label= RING_zinc_finger

PN WO9706255-A2.
XX 20-FEB-1997.
PD
XX 05-AUG-1996; 96WO-1B01022.
PF
XX 22-DEC-1995; 95US-0576956.
PR 04-AUG-1995; 95US-0511485.
XX
XX (UYOT-) UNIV OTTAWA.
PA
PI Baird S, Korneluk RG, Liston P, Mackenzie AE;
PI WPI: 1997-154262/14.
DR N-PSDB: AAT70837.
XX
XX Nucleic acid encoding an inhibitor of apoptosis polypeptide - used
PT to inhibit apoptosis in e.g. HIV or AIDS patients, and for detection
PT of susceptibility to apoptotic disease
XX
XX Claim 27: Page 72-74; 219pp: English.
PS
XX Human XIAP, HIAP-1 and HIAP-2 and murine M-XIAP, M-HIAP-1 and
CC M-HIAP-2 (AAW15581-86) are a new class of mammalian proteins that
CC are inhibitors of apoptosis (IAP) and which are characterised by
CC the presence of a ring zinc finger domain (see also AAW15587) and at
CC least one BIR (baculovirus IAP repeat) domain (see also AAW15588).
CC The HIAP amino acid sequences were deduced from cDNA clones (AAT70837
CC and AAT70838) from a human liver library. IAP polypeptides can be
CC expressed in host cells (in vitro or in vivo) and used in methods
CC for treating diseases and disorders involving apoptosis, esp. in a
CC human diagnosed as HIV-positive or as having AIDS, a
CC neurodegenerative disease, a myelodysplastic syndrome or an
CC ischaemic injury, selected from myocardial infarction, stroke,
CC reperfusion injury, or a toxin-induced liver disease.
XX
XX Sequence 604 AA:
SO

Query Match 95.6%; Score 282; DB 18; Length 604;
Best Local Similarity 93.8%; Pred. No. 2e-26; 1: Indels 0; Gaps 0;
Matches 45; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 1 PEQLASAGFYVGRNDVYKFCGCCGGLACWESGDDPWVEHAKWPRCE 48
DB 273 peglasagfyyvgsndvkcfcddgylrcwesgddpwvqhakwfpnce 320

RESULT 11
AAW13546
ID AAW13546 standard; Protein: 604 AA.
XX
XX AAW13546:
AC
XX 22-JUL-1997 (first entry)
DT
XX Human C-IAP2.
DE
XX IAP, inhibitor; apoptosis; RING finger domain; restinosis;
KW myocardial infarction; nephritis; HIV.
XX
XX Homo sapiens.
OS
XX WO9706182-A1.
PN
XX 20-FEB-1997.
PD
XX 06-AUG-1996; 96WO-US12860.
PF
XX 08-DEC-1995; 95US-0569749.
PR 08-AUG-1995; 95US-0512946.
XX
XX (TULA-) TULARIK INC.

XX
PI Goeddel DV, Rothe M;
XX WPI: 1997-154209/14.
DR N-PSDB: AAT61591.
XX
XX Nucleic acids encoding cellular inhibitor of apoptosis proteins -
PT useful for apoptosis regulation in cells to reduce or increase
PT apoptosis and for pharmacological screening
XX
XX Disclosure; Page 21-23; 35pp: English.
PS
XX The human cellular inhibitor of apoptosis proteins (C-IAP1/2 -
CC AAT61590/T61591) comprise a series of defined structural domain
CC repeats and/or a RING finger domain; in particular, at least two of
CC a first domain repeat (AAW13547 or AAW13548), a second domain repeat
CC (AAW13549 or AAW13550) and a third domain repeat (AAW13551 or AAW13552)
CC and/or a RING finger domain (AAW13553 or AAW13554), or a consensus
CC sequences derived from these human genes.
CC The nucleic acid is used for recombinant prodn. of human cellular
CC inhibitor of apoptosis protein which modulates apoptosis
CC regulation. The nucleic acids are useful in therapies where
CC increased cell-specific apoptosis is desired, e.g. in restinosis,
CC inflammatory disease states, myocardial infarction, glomerular
CC nephritis, transplant rejection and infectious diseases, e.g. HIV.
CC They can also be used in conditions requiring a reduction in
CC apoptosis.
XX
XX Sequence 604 AA:
SO

Query Match 95.6%; Score 282; DB 18; Length 604;
Best Local Similarity 93.8%; Pred. No. 2e-26; 1: Indels 0; Gaps 0;
Matches 45; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 1 PEQLASAGFYVGRNDVYKFCGCCGGLACWESGDDPWVEHAKWPRCE 48
DB 273 peglasagfyyvgsndvkcfcddgylrcwesgddpwvqhakwfpnce 320

RESULT 12
AAW69295
ID AAW69295 standard; Protein: 604 AA.
XX
XX AAW69295:
AC
XX 13-NOV-1998 (first entry)
DT
XX Human HIAP-1 protein.
DE
XX Inhibitor of apoptosis protein; apoptosis enhancer; NAIP polypeptide;
KW proliferative disease; IAP; therapy; cancer; human; HIAP-1 protein.
XX
XX Homo sapiens.
OS
XX WO9835693-A2.
PN
XX 20-AUG-1998.
PD
XX 13-FEB-1998; 98WO-1B00781.
PF 13-FEB-1997; 97US-0800929.
PR
XX 13-FEB-1997; 97US-0800929.
XX
XX (UYOT-) UNIV OTTAWA.
PA
PI Baird S, Korneluk R, Liston P, Mackenzie AE, Pratt C;
PI Tsang B;
PI WPI: 1998-467164/40.
DR N-PSDB: AAV55039.
XX
XX Inducing apoptosis in proliferative mammalian cells with inhibitor
PT of IAP or NAIP polypeptide - also methods for prognosis based on

CC A method has been developed of defining a set of compounds that modulate

PS Example 13; Columns 45-50; 33pp; English.

CC The invention provides antisense compounds of 8-30 nucleotides that
CC inhibit the expression of human cellular inhibitor of apoptosis-2
CC (c-IAP-2). The antisense compounds may be used for diagnostics,
CC therapeutics (for modulating the expression of c-IAP-2), prophylaxis
CC (e.g., to prevent or delay infection, inflammation, or tumor formation),
CC as research reagents (e.g., to distinguish between members of a biological

CC pathway and in kts. The present sequence represents the human cellular
CC inhibitor of apoptosis-2.
xx
SQ Sequence 604 AA;

Query Match	95.6%	Score 282;	DB 20;	Length 604;
Best Local Similarity	93.8%;	Pred. No. 2e-26;		
Matches	45;	Conservative	2;	Mismatches 1; Indels 0; Gaps 0;

```

Qy      1 pGL1ASAGYYVGRNDYKCFCCDGGSLRCRWESGDDPWWYEHAKKAPRCE 48
          |||.....|.....|.....|.....|.....|.....|.....|.....|
Db      273 pGL1ASAGFYVGNDDYKCFCCDGGSLRCRWESGDDPWWYEHAKKAPRCE 320

```

	Matches	45;	Conservative	1;	Mismatches	2;	Indels	0;	Gaps	0;
Qy	1	PEGLASAGSYVGRNDYVKCFCCDGLRCRWSSGDDP	WVHAHAKFFPCE	48						
Db	280	peglasagfyyvdrndyvkctccdgslrcwepgddp	ielakkfprce	327						

Query Match	95.6%;	Score 282;	DB 18;	Length 612;
Best Local Similarity	93.8%;	Pred. No. 2e-26;		
